AU2016365366B2 - Protein kinase inhibitor, preparation method and medical use thereof - Google Patents

Protein kinase inhibitor, preparation method and medical use thereof Download PDF

Info

Publication number
AU2016365366B2
AU2016365366B2 AU2016365366A AU2016365366A AU2016365366B2 AU 2016365366 B2 AU2016365366 B2 AU 2016365366B2 AU 2016365366 A AU2016365366 A AU 2016365366A AU 2016365366 A AU2016365366 A AU 2016365366A AU 2016365366 B2 AU2016365366 B2 AU 2016365366B2
Authority
AU
Australia
Prior art keywords
compound
isotopically
racemate
diastereomer
mesomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016365366A
Other languages
English (en)
Other versions
AU2016365366A1 (en
Inventor
Heng Li
Wenjian LIU
Lei YIN
Dianxi ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016365366(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of AU2016365366A1 publication Critical patent/AU2016365366A1/en
Application granted granted Critical
Publication of AU2016365366B2 publication Critical patent/AU2016365366B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2016365366A 2015-11-30 2016-11-28 Protein kinase inhibitor, preparation method and medical use thereof Ceased AU2016365366B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510856641.1 2015-11-30
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途
PCT/CN2016/107455 WO2017092635A1 (zh) 2015-11-30 2016-11-28 一种蛋白激酶抑制剂及其制备方法和医药用途

Publications (2)

Publication Number Publication Date
AU2016365366A1 AU2016365366A1 (en) 2018-05-17
AU2016365366B2 true AU2016365366B2 (en) 2021-03-04

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016365366A Ceased AU2016365366B2 (en) 2015-11-30 2016-11-28 Protein kinase inhibitor, preparation method and medical use thereof

Country Status (21)

Country Link
US (2) US11091476B2 (https=)
EP (1) EP3385262B1 (https=)
JP (2) JP6921101B2 (https=)
KR (1) KR20180083421A (https=)
CN (3) CN106810536A (https=)
AU (1) AU2016365366B2 (https=)
BR (1) BR112018010879A2 (https=)
CA (1) CA3002884A1 (https=)
CO (1) CO2018005854A2 (https=)
DK (1) DK3385262T3 (https=)
ES (1) ES2928169T3 (https=)
HU (1) HUE060152T2 (https=)
IL (1) IL259711B (https=)
MA (1) MA42341B2 (https=)
MX (1) MX387207B (https=)
PH (1) PH12018550049A1 (https=)
PT (1) PT3385262T (https=)
RU (1) RU2749437C2 (https=)
UA (1) UA124001C2 (https=)
WO (1) WO2017092635A1 (https=)
ZA (1) ZA201803531B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
AU2018354972B2 (en) 2017-10-27 2021-07-08 Fresenius Kabi Oncology Ltd. An improved process for the preparation of ribociclib and its salts
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
WO2019170055A1 (zh) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途
AU2020215684B2 (en) * 2019-01-29 2025-08-21 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
CN114364668B (zh) * 2019-06-21 2024-07-16 甘李药业股份有限公司 Cdk4/6抑制剂、及其盐和中间体的制备方法
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
US11685744B2 (en) * 2020-09-21 2023-06-27 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
IL316942A (en) * 2020-12-18 2025-01-01 Prelude Therapeutics Inc CDK inhibitors and their use as drugs
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
CN117222636A (zh) * 2021-04-12 2023-12-12 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2023040914A1 (zh) * 2021-09-14 2023-03-23 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118339157A (zh) * 2021-12-24 2024-07-12 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
CN117658987A (zh) * 2022-09-08 2024-03-08 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
WO2024066986A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160340A1 (en) * 2008-12-22 2010-06-24 Coates David A Protein kinase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
ES2251677T3 (es) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
EP2283009B1 (en) 2008-05-16 2012-08-29 F. Hoffmann-La Roche AG Inhibitors of jnk
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2909194A1 (en) * 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
KR102765806B1 (ko) 2017-09-05 2025-02-10 블랙손 테라퓨틱스, 인크. 바소프레신 수용체 길항제 및 그와 관련된 제품 및 방법
CN117222636A (zh) 2021-04-12 2023-12-12 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160340A1 (en) * 2008-12-22 2010-06-24 Coates David A Protein kinase inhibitors

Also Published As

Publication number Publication date
HUE060152T2 (hu) 2023-02-28
EP3385262A4 (en) 2019-06-19
MX387207B (es) 2025-03-18
DK3385262T3 (da) 2022-10-10
CN113956238B (zh) 2023-07-14
WO2017092635A1 (zh) 2017-06-08
CN113956238A (zh) 2022-01-21
BR112018010879A2 (pt) 2018-11-21
EP3385262A1 (en) 2018-10-10
US11787801B2 (en) 2023-10-17
MA42341A1 (fr) 2018-06-29
UA124001C2 (uk) 2021-07-07
RU2749437C2 (ru) 2021-06-10
US11091476B2 (en) 2021-08-17
RU2018122864A3 (https=) 2020-03-17
CO2018005854A2 (es) 2018-06-20
IL259711A (en) 2018-07-31
CN108290864B (zh) 2022-05-10
RU2018122864A (ru) 2020-01-13
EP3385262B1 (en) 2022-07-13
CN106810536A (zh) 2017-06-09
PT3385262T (pt) 2022-10-18
PH12018550049A1 (en) 2018-10-29
MA42341B2 (fr) 2021-05-31
MX2018006370A (es) 2018-09-24
ZA201803531B (en) 2021-10-27
AU2016365366A1 (en) 2018-05-17
JP2021138737A (ja) 2021-09-16
ES2928169T3 (es) 2022-11-15
IL259711B (en) 2022-08-01
CA3002884A1 (en) 2017-06-08
US20200165239A1 (en) 2020-05-28
JP6921101B2 (ja) 2021-08-18
KR20180083421A (ko) 2018-07-20
JP2019500413A (ja) 2019-01-10
CN108290864A (zh) 2018-07-17
US20210371418A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
AU2016365366B2 (en) Protein kinase inhibitor, preparation method and medical use thereof
CN103384670B (zh) 取代的咪唑并[1,2-b]哒嗪
JP2019500413A5 (https=)
JP2020502065A (ja) ８，９−ジヒドロイミダゾール［１，２−ａ］ピリミド［５，４−ｅ］ピリミジン−５（６Ｈ）−ケトン類化合物
JP2024531477A (ja) Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用
AU2018206111B2 (en) Substituted fused heteroaryl compound serving as a kinase inhibitor, and applications thereof
CN119661557A (zh) 作为激酶抑制剂的二取代含氮五元杂芳基化合物及其应用
AU2019316858B2 (en) Smad3 inhibitors
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
EP3369734A1 (en) Kinase inhibitor, and preparing method and pharmaceutical use thereof
WO2019189732A1 (ja) 光学活性な架橋型環状２級アミン誘導体
AU2017389818B2 (en) Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
KR20240041340A (ko) 피롤로피리미딘 유도체 화합물 및 이의 용도
CN120092008A (zh) 取代的杂芳基双环化合物作为usp1抑制剂及其应用
KR20240128040A (ko) 2 고리성 골격을 갖는 1h-피라졸-3-아민 유도체
EP4310081A1 (en) Ctla-4 small molecule degradation agent and application thereof
HK1260629A1 (en) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof
HK1260629B (en) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof
EP4581032A1 (en) Triazine compounds and uses thereof
JP2026507185A (ja) Ｐａｒｐ阻害剤としての置換窒素含有三環式化合物及びその使用
HK1185881B (en) Substituted imidazo[1,2-b]pyridazines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired